Clarametyx Biosciences Inc. develops immune-enabling biologic therapies that target biofilms, the protective barriers surrounding bacteria, to combat life-threatening infections. Their technology aims to reduce antibiotic resistance by providing an alternative approach to traditional antibiotic treatments.
Funding
$44M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Bacterial biofilms, protective barriers surrounding bacteria, contribute to persistent and difficult-to-treat infections. These biofilms enhance antibiotic resistance, making traditional antibiotic treatments less effective against life-threatening infections.
Solution
Clarametyx Biosciences develops biologic therapies that target and disrupt bacterial biofilms, offering an alternative approach to combat infections and reduce antibiotic resistance. Their immune-enabling therapies aim to weaken the biofilm's protective structure, allowing the body's immune system to more effectively clear the infection. This approach seeks to address the limitations of traditional antibiotics by targeting the biofilm directly, rather than the bacteria themselves. By disrupting the biofilm, the therapies aim to improve treatment outcomes for patients with challenging bacterial infections.
Target Audience
The primary target audience includes patients with life-threatening bacterial infections, particularly those complicated by biofilms, and healthcare providers seeking alternative treatment options to combat antibiotic resistance.
Features
- Biologic therapies designed to target and disrupt bacterial biofilms.
- Focus on immune-enabling mechanisms to enhance the body's natural defenses against infection.
- Aims to reduce antibiotic resistance by providing an alternative to traditional antibiotic treatments.